CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback